课题基金 / 基金详情

CLINICAL TRIAL: PK AND BIOL STUDY OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) IN P

CLINICAL TRIAL: PK AND BIOL STUDY OF SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) IN P
临床试验:辛酰苯胺异羟肟酸(SAHA)在 P 中的 PK 和生物研究
批准号:
7718721
负责人:
John Sarantopoulos
金额:
$0.02万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2008-05-31

项目摘要

项目成果

John Sarantopoulos的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目标: 主要 -根据客观反应和进展速度,确定SAHA在免疫治疗和/或生物治疗失败超过2个疗程的晚期肾细胞癌(RCC)患者中的抗肿瘤活性,或在不适合接受基于IL-2治疗的以前未治疗的患者中。 次要的 -根据NCI/CTC v3.0标准,进一步评估SAHA的安全性和耐受性,该剂量为300 mg,每天两次,每周连续三天,根据NCI/CTC v3.0标准,通过毒性概况、发生率和分级确定 -为了进一步评估SAHA的生物活性,根据无进展存活率、开始治疗后12个月的存活率和总存活率来确定。 -研究SAHA的血浆稳态浓度与药物对外周血单个核细胞(PBMC)和肿瘤组织中乙酰化组蛋白表达的影响之间的药效学关系。 -分析SAHA对细胞凋亡、血管生成及下游靶点和基因转录的生物学作用。 -将这些生物测量的变化与患者预后指数相关联。 研究计划: 成年男性和女性晚期肾癌患者,转移性或无法手术,预计将参与研究。 方法: 有资格在退伍军人管理局/GCRC接受治疗的潜在患者将接受SAHA治疗。 位于南得克萨斯州退伍军人医疗保健系统奥迪·墨菲分部的GCRC预计将招收约5名患者。 临床相关性: SAHA是一种有效的HDAC活性抑制剂,直接与HDAC酶的催化口袋结合。在培养的转化细胞中,SAHA导致G1或G2期细胞周期停滞、凋亡或分化。在小鼠体内注射SAHA可显著抑制人前列腺癌移植瘤的生长;SAHA剂量(50 mg/kg/天)可观察到肿瘤消退,且未产生毒副作用。在急性早幼粒细胞白血病(APL)耐药转基因小鼠模型中,SAHA联合维甲酸可诱导白血病缓解并延长存活时间。在小鼠的人乳腺癌和人结肠癌异种移植瘤中,腹腔注射SAHA均能显著抑制肿瘤生长。观察到SAHA剂量(100毫克/公斤/天)对肿瘤生长有抑制作用,且不产生毒副作用。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVES: Primary - To determine the antitumor activity of SAHA in patients with advanced renal cell carcinoma (RCC) who have failed up to 2 lines of prior immunotherapy and/or bilogical therapy or in previously untreated patients who are not appropriate candidates to receive IL-2 based treatment, as determined by objective response and progression rates. Secondary - To further evaluate the safety and tolerability of SAHA given at a dose of 300mg twice daily for 3 consecutive days every week in this patient population as determined by toxicity profile, incidence and rating according to NCI/CTC v3.0 criteria - To further evaluate the biologic activity of SAHA as determined by progression free survival, survival rate at 12 months after initiation of treatment and overall survival. - To characterize the pharmacodynamic relationships between the plasma steady state concentration of SAHA and the drug effect on expression of acetylated histones in peripheral blood mononuclear cells (PBMC) and tumor tissue where the tumor is accessible for biopsy. - To analyze the biologic effects of SAHA on apoptosis, angiogenesis and downstream targets and gene transcription. - To correlate changes in these biological measurements with indices of patient outcome. RESEARCH PLAN: Adult male and female patients with advanced renal cell carcinoma, metastatic or inoperable, are expected to participate in the study. METHODS: Potential patients eligible for care at the VA/GCRC will be treated with SAHA. Enrollment of about 5 patients is anticipated at the GCRC, located at the South Texas Veterans Health Care System, Audie Murphy Division. CLINICAL RELEVANCE: SAHA is a potent inhibitor of HDAC activity and binds directly to the catalytic pocket of HDAC enzymes. SAHA causes G1 or G2 phase cell-cycle arrest, apoptosis, or differentiation in cultured transformed cells. Intraperitoneal administration of SAHA causes significant tumor growth inhibition in human prostate cancer xenografts in mice; tumor regressions were observed at SAHA doses (50 mg/kg/day) that did not produce toxic side effects. Intraperitoneal administration of SAHA in combination with retinoic acid induced leukemic remission and prolonged survival in a therapy-resistant transgenic mouse model of acute promyelocytic leukemia (APL). Intraperitoneal administration of SAHA causes significant tumor growth inhibition in both human breast carcinoma and human colon carcinoma cancer xenografts in mice. Tumor growth inhibition was observed at SAHA doses (100 mg/kg/day) that do not produce toxic side effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DATA SAFETY AND MONITORING BOARDS
CLINICAL TRIAL: PH I PK STUDY OF TEMSIROLIMUS (CCI-779) IN PTS WITH IMPAIRED LIV
DATA SAFETY AND MONITORING BOARDS
DATA SAFETY AND MONITORING BOARDS
海外基金